002821 Asymchem Laboratories(Tianjin)Co.,Ltd.
Closed 04-16 15:00:00
117.41
-0.44
-0.37%
High119.40Low115.50Vol8.41M
Open117.24D1 Closing117.85Amplitude3.31%
Mkt Cap42.39BTradable Cap37.22BTotal Shares361.00M
T/O988.00MT/O Rate2.65%Tradable Shares317.00M
P/B2.41ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Asymchem Laboratories Expands TIDES Production Capacity, Enhancing Drug Service Capabilities
Deep News  ·  14:31
Asymchem Laboratories Expands TIDES Production Capacity, Enhancing Drug Service Capabilities
J.P. Morgan Increases Stake in Asymchem by 95,600 Shares at HK$97.68 Per Share
Deep News  ·  04-14 07:50
J.P. Morgan Increases Stake in Asymchem by 95,600 Shares at HK$97.68 Per Share
Asymchem schedules board meeting to review first-quarter results
Reuters  ·  04-13
Asymchem schedules board meeting to review first-quarter results
Norges Bank Reduces Stake in Asymchem by 263,200 Shares at HK$104.64 Each
Stock News  ·  04-08
Norges Bank Reduces Stake in Asymchem by 263,200 Shares at HK$104.64 Each
Bocom International Maintains Buy Rating on Asymchem, Raises Target Price to HK$123.2
Deep News  ·  04-03
Bocom International Maintains Buy Rating on Asymchem, Raises Target Price to HK$123.2
Asymchem Laboratories Shares Experience Abnormal Trading Fluctuations, No Undisclosed Matters
Stock News  ·  04-01
Asymchem Laboratories Shares Experience Abnormal Trading Fluctuations, No Undisclosed Matters
Robust CXO Earnings Boost Performance: Huabao Fund's HK Connect Medical ETF and Medical ETF Rise Up to 2%
Deep News  ·  03-31
Robust CXO Earnings Boost Performance: Huabao Fund's HK Connect Medical ETF and Medical ETF Rise Up to 2%
Asymchem Laboratories Reports Annual Profit Growth of 19.35%
Stock News  ·  03-30
Asymchem Laboratories Reports Annual Profit Growth of 19.35%
Asymchem Laboratories proposes final dividend of RMB 13 per 10 shares
Reuters  ·  03-30
Asymchem Laboratories proposes final dividend of RMB 13 per 10 shares
Asymchem FY25 net profit climbs 19.35% to RMB 1.1 billion; revenue rises to RMB 6.7 billion
Reuters  ·  03-30
Asymchem FY25 net profit climbs 19.35% to RMB 1.1 billion; revenue rises to RMB 6.7 billion
BRIEF-Asymchem Laboratories (Tianjin) 2025 Net Profit Up 19.4% Y/Y
Reuters  ·  03-30
BRIEF-Asymchem Laboratories (Tianjin) 2025 Net Profit Up 19.4% Y/Y
Schroders PLC Increases Stake in Asymchem Laboratories with 88,500 Shares Purchase
Stock News  ·  03-30
Schroders PLC Increases Stake in Asymchem Laboratories with 88,500 Shares Purchase
Asymchem Laboratories Tianjin H shareholders vote on proxy appointments; meeting set for April 17, 2026
Reuters  ·  03-25
Asymchem Laboratories Tianjin H shareholders vote on proxy appointments; meeting set for April 17, 2026
Asymchem Laboratories Tianjin schedules board meeting to approve annual results and consider final dividend
Reuters  ·  03-16
Asymchem Laboratories Tianjin schedules board meeting to approve annual results and consider final dividend
Asymchem to Repurchase and Cancel Restricted A-Shares Under 2025 Equity Incentive Plan
Stock News  ·  03-13
Asymchem to Repurchase and Cancel Restricted A-Shares Under 2025 Equity Incentive Plan
Asymchem Laboratories Tianjin to Cancel 61,000 Restricted A Shares in Capital Reduction
Reuters  ·  03-13
Asymchem Laboratories Tianjin to Cancel 61,000 Restricted A Shares in Capital Reduction
AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
GlobeNewswire  ·  03-09
AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
BRIEF-Citigroup's Long Position In H-Shares Of Asymchem Laboratories (Tianjin) Increases To 11.67% On Feb 19 From 9.34%, HKEX Filing Shows
Reuters  ·  02-25
BRIEF-Citigroup's Long Position In H-Shares Of Asymchem Laboratories (Tianjin) Increases To 11.67% On Feb 19 From 9.34%, HKEX Filing Shows
Citigroup's Long Position in H-Shares of Asymchem Laboratories (Tianjin) Increases to 11.67% on Feb 19 From 9.34% - HKEX
THOMSON REUTERS  ·  02-25
Citigroup's Long Position in H-Shares of Asymchem Laboratories (Tianjin) Increases to 11.67% on Feb 19 From 9.34% - HKEX
JPMorgan Boosts Stake in Asymchem with 9,400 Share Purchase at HK$87.56 Each
Stock News  ·  02-13
JPMorgan Boosts Stake in Asymchem with 9,400 Share Purchase at HK$87.56 Each

Introduction

Company Name.
凯莱英医药集团(天津)股份有限公司
Industry:
医药制造业
Listing Date:
2016-11-18
Main Business:
　　凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是小分子CDMO解决方案、新兴业务。凯莱英生物AsymBio偶联药物开发平台成功入围第12届WorldADCAwards“BestADCPlatformTechnology”奖项，印证了凯莱英生物在全球抗体偶联药物CDMO领域的卓越地位。
Issue price:
30.53